Lessons learned from a multi‐data source research collaboration: The mirabegron post‐authorization safety study program
Pharmacoepidemiology and Drug Safety · 2024
DOI: 10.1002/pds.5799 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2024. Verfasst von Stefan de Vogel und 14 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacovigilance, Astellas Pharma B.V., Leiden, The Netherlands. Hauptthemen laut MEDLINE: Thiazoles, Product Surveillance, Postmarketing, Urinary Bladder, Overactive, Acetanilides. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Astellas Pharma US.
Abstract (Originalsprache)
Background
Many factors contribute to developing and conducting a successful multi‐data source, non‐interventional, post‐authorization safety study (NI‐PASS) for submission to multiple health authorities. Such studies are often large undertakings; evaluating and sharing lessons learned can provide useful insights to others considering similar studies.
Objectives
We discuss challenges and key methodological and organizational factors that led to the delivery of a successful post‐marketing requirement (PMR)/PASS program investigating the risk of cardiovascular and cancer events among users of mirabegron, an oral medication for the treatment of overactive bladder.
Results
We provide context and share learnings, including sections on research program collaboration, scientific transparency, organizational approach, mitigation of uncertainty around potential delays, validity of study outcomes, selection of data sources and optimizing patient numbers, choice of comparator groups and enhancing precision of estimates of associations, potential confounding and generalizability of study findings, and interpretation of results.
Conclusions
This large PMR/PASS program was a long‐term commitment from all parties and benefited from an effective coordinating center and extensive scientific interactions across research partners, scientific advisory board, study sponsor, and health authorities, and delivered useful learnings related to the design and organization of multi‐data source NI‐PASS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmacovigilance, Astellas Pharma B.V., Leiden, The Netherlands.
- Epidemiology, Optum, Boston, Massachusetts, USA.
- Epidemiology, RTI Health Solutions, Barcelona, Spain.
- Epidemiology, RTI Health Solutions, Research Triangle Park, Durham, North Carolina, USA.
- Public Health, University of Southern Denmark, Odense, Denmark.
- Medicine, Centre for Pharmacoepidemiology, Karolinska Institutet, Solna, Sweden.
ORCID-Profile: Stefan de Vogel, John D Seeger, Alejandro Arana, Andrea V Margulis, Susana Perez-Gutthann, Jesper Hallas, Marie Linder
Förderung
- Astellas Pharma US
Zitieren
APA
de Vogel, S., Seeger, J. D., Arana, A., Margulis, A. V., McQuay, L. J., Perez-Gutthann, S., Hallas, J., Kristiansen, N. S., Linder, M., Odsbu, I., Suehs, B., Xu, Y., Uribe, C., Appenteng, K., & Robinson, N. J. (2024). Lessons learned from a multi‐data source research collaboration: The mirabegron post‐authorization safety study program. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.5799
Vancouver
de Vogel S, Seeger JD, Arana A, Margulis AV, McQuay LJ, Perez-Gutthann S, et al. Lessons learned from a multi‐data source research collaboration: The mirabegron post‐authorization safety study program. Pharmacoepidemiology and Drug Safety. 2024. doi:10.1002/pds.5799
BibTeX
@article{deVogel2024,
author = {de Vogel, Stefan and Seeger, John D and Arana, Alejandro and Margulis, Andrea V and McQuay, Lisa J and Perez-Gutthann, Susana and Hallas, Jesper and Kristiansen, Nina Sahlertz and Linder, Marie and Odsbu, Ingvild and Suehs, Brandon and Xu, Yihua and Uribe, Claudia and Appenteng, Kwame and Robinson, Noah Jamie},
title = {Lessons learned from a multi‐data source research collaboration: The mirabegron post‐authorization safety study program},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2024},
doi = {10.1002/pds.5799}
}
EUVIMED